Ihoken Proposes Revision of Compensation Guidelines to Include Compensation for Injury Due to Anticancer Drugs

Ihoken Chairman Takayoshi Tokuyasu The Japan Pharmaceutical Industry Legal Affairs Association, or Ihoken, presented a proposal to revise the industry’s voluntary “compensation guidelines,” which determine the scope of compensation provided to subjects in the event of injuries related to sponsor-initiated...read more